Literature DB >> 3279135

Cryptococcal meningitis in patients with AIDS.

W E Dismukes1.   

Abstract

The Cryptococcus has become a major cause of meningitis in patients infected with the human immunodeficiency virus (HIV), and the expression of cryptococcal infection in this population of patients is quite unique. Often the infection is devoid of inflammatory response and is associated with very high antigen and fungal titers. Response to amphotericin therapy is erratic, and relapse is common. We have asked Dr. William E. Dismukes, principal investigator of the NIAID Mycoses Study Group, to discuss the following clinical questions: When and how does cryptococcal infection in HIV-infected patients present? How does it differ in HIV-infected and non-HIV-infected individuals? How is the diagnosis established? What is the sensitivity of the CSF cryptococcal antigen test? Is the serum antigen test of any value? What is the best way to treat patients--the recommended drugs, dosages, and duration of therapy? Is maintenance therapy necessary, and finally, what drugs are available for it? [Please note that an AIDS training program is now available for members of the Infectious Diseases Society of America and that details of this program appear in the Notices section of this Journal issue (pages 859-60).]

Entities:  

Mesh:

Year:  1988        PMID: 3279135     DOI: 10.1093/infdis/157.4.624

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  78 in total

1.  Interaction between fluconazole and rifampicin.

Authors:  R J Coker; D R Tomlinson; J Parkin; J R Harris; A J Pinching
Journal:  BMJ       Date:  1990-10-06

2.  An ounce of prevention - The new wave in HIV therapy.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1992-03

3.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

4.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D.

Authors:  D Garcia-Hermoso; S Mathoulin-Pélissier; B Couprie; O Ronin; B Dupont; F Dromer
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

Review 6.  Diagnosing fungal infections in immunocompromised hosts.

Authors:  C M Tang; J Cohen
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

7.  Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.

Authors:  Ashok K Chaturvedi; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  Proteomics       Date:  2013-12       Impact factor: 3.984

8.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.

Authors:  R J Coker; D Bell; B S Peters; S M Murphy
Journal:  Genitourin Med       Date:  1992-02

10.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.